In Silico Modeling of a Mathematically Optimized Staggered Epigenetic Priming Regimen Range: Candidate 1 (WA / Quercetin / Silibinin Architecture)

This dataset establishes public domain Prior Art for a mathematically optimized, multi-compound in silico model designed to induce cellular chemosensitisation. While the isolated anti-neoplastic and chemoprotective properties of Withaferin A (WA), Quercetin, and Silibinin are documented in baseline oncology literature, their simultaneous kinetic orchestration remains unoptimized. This model introduces a highly specific, computational blueprint using Nelder-Mead optimization to bracket peak synergistic tumor cell cytotoxicity while actively driving metabolic liability indices down. By introducing a precisely timed staggered priming window and a pre-infusion metabolic washout barrier, this hypothesis maps out a mechanism to maximize chemosensitisation while bypassing direct Drug-Drug Interaction (DDI) liabilities. This data is donated openly to the cancer research community to serve as an unpatentable baseline for future in vitro and in vivo validation. Defensive Anti-Bracketing Declaration This disclosure covers and invalidates the novelty of the entire operational sequence within the broad ranges of T-48h to T-24h (initial priming), T-24h to T-12h (kinetic refreshing), and T-12h to T0 (metabolic washout), barring any commercial entity from claiming monopoly utility/method patent rights over any component of this timing continuum.